Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutation

NCT04470076 is registered in ClinicalTrials.gov with Fifth Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT04470076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04470076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutation
Lead sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 2
Overall status
Unknown status
Start date
July 10, 2020
Completion date
July 30, 2023
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, egfr activating mutation, egfr tki, non small cell lung cancer, surgery